Ultrasound drugs expected to receive stricter warning labels

10/7/2007 | Wall Street Journal, The

Bristol-Myers Squibb Co.'s Definity, General Electric Co.'s Optison and several other drugs used with ultrasound imaging machines to diagnose heart diseases may come with stronger, black-box warning labels to tell doctors not to use the drugs in patients with unstable angina, acute heart attacks and unstable cardiopulmonary disease and to monitor patients' heartbeats for trouble with an electrocardiogram, sources said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC